Keyphrases
In Vivo Efficacy
100%
Mycobacterium Abscessus
100%
Relebactam
100%
Avibactam
100%
Imipenem
83%
Ceftazidime
50%
M. Abscessus Complex
50%
Treatment Options
33%
Lactams
33%
Meropenem
33%
Commercially Available
16%
Effective Treatment
16%
Wide-ranging
16%
Lung
16%
β-lactamase Inhibitor
16%
Antimicrobial Resistance
16%
Combination Therapy
16%
Inactivity
16%
Current Treatment
16%
Minimum Bactericidal Concentration
16%
Treatment Regime
16%
Respiratory Conditions
16%
Triplicate
16%
β-lactam Antibiotics
16%
Antimicrobial Resistance Mechanisms
16%
Frontline Treatment
16%
Partner Drug
16%
Complex Infection
16%
Epithelial Lining Fluid
16%
Medicine and Dentistry
In Vitro
100%
Imipenem
100%
Mycobacterium abscessus
100%
Relebactam
100%
Avibactam
100%
Infection
80%
Ceftazidime
60%
Antibiotic Resistance
40%
Meropenem
40%
Lactam
40%
Lung
20%
Combination Therapy
20%
Prevalence
20%
Bactericidal Activity
20%
Penicillinase
20%
Epithelial Lining Fluid
20%
β-Lactam antibiotic
20%
Pharmacology, Toxicology and Pharmaceutical Science
Imipenem
100%
Mycobacterium abscessus
100%
Relebactam
100%
Avibactam
100%
Infection
80%
Ceftazidime
60%
Lactam
40%
Antimicrobial Resistance
40%
Meropenem
40%
Prevalence
20%
Combination Therapy
20%
Penicillinase
20%
Minimum Inhibitory Concentration
20%
Minimum Bactericidal Concentration
20%
Beta Lactam Antibiotic
20%
Immunology and Microbiology
Mycobacterium abscessus
100%
Antimicrobial Resistance
100%
Prevalence
50%
Minimum Inhibitory Concentration
50%
Bactericidal Activity
50%
Minimum Bactericidal Concentration
50%
Epithelial Lining Fluid
50%